|
|
Post by orlon on Feb 3, 2016 18:55:18 GMT -5
I listened to the call then read comments on both this board and the other one. So far saw a lot a negative points on both boards from calling Pffefer and the management team morons..the other board, to how GS is planning a downgrade, (I don't understand why a company so great and powerful like GS would waste time downgrading a stock under a dollar?...a bit of sarcasm here) I did not see anyone address the fact that MNKD can do little until April, when full control of AFREZZA is returned by Sanofi. I personally liked the fact that Matt addressed the individual investor questions/comments before he took questions from the rocket scientists at GS, Piper, and whoever the other guy was. I'm willing to wait, give them a chance to put their plan in action and then evaluate. I've been negative on the company myself in the past but Hakan is gone as will be the elephant in the room Sanofi in April. Maybe Matt and team have learned the Jacques Clouseau lesson in partners...trust everyone but trust no one.
|
|
|
|
Post by sccrbrg on Feb 3, 2016 19:06:24 GMT -5
I would gladly have given up the shareholder question and answer for a feasible plan of action that will fund the company through 2016.
That's why everyone is so down on the call. If anything all they managed to do was introduce more doubt about being able to stave off BK. If they had answered that question and nothing else we would be over $1 right now instead of in free fall.
|
|
|
|
Post by mnkdfann on Feb 3, 2016 19:20:45 GMT -5
(I don't understand why a company so great and powerful like GS would waste time downgrading a stock under a dollar?...a bit of sarcasm here) I know you are being sarcastic but, for those who wonder about this, the fact remains that MNKD is still a 400+ million dollar market cap company and is worthy of attention. There are companies with several times the share price with a much smaller market cap. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Feb 3, 2016 19:52:13 GMT -5
I listened to the call then read comments on both this board and the other one. So far saw a lot a negative points on both boards from calling Pffefer and the management team morons..the other board, to how GS is planning a downgrade, (I don't understand why a company so great and powerful like GS would waste time downgrading a stock under a dollar?...a bit of sarcasm here) I did not see anyone address the fact that MNKD can do little until April, when full control of AFREZZA is returned by Sanofi. I personally liked the fact that Matt addressed the individual investor questions/comments before he took questions from the rocket scientists at GS, Piper, and whoever the other guy was. I'm willing to wait, give them a chance to put their plan in action and then evaluate. I've been negative on the company myself in the past but Hakan is gone as will be the elephant in the room Sanofi in April. Maybe Matt and team have learned the Jacques Clouseau lesson in partners...trust everyone but trust no one. Maybe we didnt hear the same thing. If one intends to have complete control back in April they would not make a comment about an extension being needed. I view that as preparing to let us know its not going to be handed over by April. |
|
|
|
Post by mnholdem on Feb 3, 2016 20:04:43 GMT -5
That's a fair assessment. If people read the January PR that announced the termination, they'll read that transfer can take place April 5 if Sanofi's reason is that Afrezza is not commercially feasible. But you'll notice in the PR that Sanofi may choose an alternate 6-month notice for any reason, which would put the termination date on July 4.
One of the questions I had asked to be addressed was if Sanofi has communicated the official termination date to MannKind. I'll need to read the transcript to determine if Matt stated that the termination date "could be" April 5 or "will be".
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Feb 3, 2016 20:13:13 GMT -5
That's a fair assessment. If people read the January PR that announced the termination, they'll read that transfer can take place April 5 if Sanofi's reason is that Afrezza is not commercially feasible. But you'll notice in the PR that Sanofi may choose an alternate 6-month notice for any reason, which would put the termination date on July 4. One of the questions I had asked to be addressed was if Sanofi has communicated the official termination date to MannKind. I'll need to read the transcript to determine if Matt stated that the termination date "could be" April 5 or "will be". April for US rights and July for all rights I guess internationalVALENCIA, Calif., Jan. 05, 2016 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) today announced the termination of its license and collaboration agreement with sanofi-aventis U.S. LLC for the development and commercialization of Afrezza® (insulin human) Inhalation Powder. The parties will promptly commence transition discussions in order to effect a smooth and orderly transition in the development and commercialization of Afrezza from Sanofi to MannKind over the next 90 - 180 days. In any event, termination of the license agreement in its entirety will be effective no later than six months from the effective date of Sanofi's notice of termination, or July 4, 2016. - See more at: investors.mannkindcorp.com/releasedetail.cfm?ReleaseID=948810#sthash.rRxLhGLH.dpuf |
|
|
|
Post by patten1962 on Feb 3, 2016 20:23:12 GMT -5
That's a fair assessment. If people read the January PR that announced the termination, they'll read that transfer can take place April 5 if Sanofi's reason is that Afrezza is not commercially feasible. But you'll notice in the PR that Sanofi may choose an alternate 6-month notice for any reason, which would put the termination date on July 4. One of the questions I had asked to be addressed was if Sanofi has communicated the official termination date to MannKind. I'll need to read the transcript to determine if Matt stated that the termination date "could be" April 5 or "will be". I was told by Sanofi rep they are in until July. But who knows if he is right? I was pleased with the call. Question is, people that are long, Are they looking at the call objectively? |
|
|
|
Post by sccrbrg on Feb 3, 2016 20:27:29 GMT -5
That's a fair assessment. If people read the January PR that announced the termination, they'll read that transfer can take place April 5 if Sanofi's reason is that Afrezza is not commercially feasible. But you'll notice in the PR that Sanofi may choose an alternate 6-month notice for any reason, which would put the termination date on July 4. One of the questions I had asked to be addressed was if Sanofi has communicated the official termination date to MannKind. I'll need to read the transcript to determine if Matt stated that the termination date "could be" April 5 or "will be". I was told by Sanofi rep they are in until July. But who knows if he is right? I was pleased with the call. Question is, people that are long, Are they looking at the call objectively? Based on your recent posts - I would say that you are the one that is not looking at this objectively, or at least not aware of enough of the company history to be wholly objective. You do realize that at the current burn rate they will be out of money in July? Getting them the rights back at the point does them no good, and if they can't sign another partner until they get the rights back then that basically spells BK unless Mann steps in again and drops a huge loan. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Feb 3, 2016 20:31:17 GMT -5
That's a fair assessment. If people read the January PR that announced the termination, they'll read that transfer can take place April 5 if Sanofi's reason is that Afrezza is not commercially feasible. But you'll notice in the PR that Sanofi may choose an alternate 6-month notice for any reason, which would put the termination date on July 4. One of the questions I had asked to be addressed was if Sanofi has communicated the official termination date to MannKind. I'll need to read the transcript to determine if Matt stated that the termination date "could be" April 5 or "will be". I read it that way from day one but half the members here labeled it as FUD One of the moderators or board owners even corrected me that MNKD had the rights now. Why would SNY give it back early? They dug the knife in our back with their statement that Afrezza has no shot at gaining any traction and now they are going to turn it over early? If SNY truly feels threatened by MNKD then why would they give them a chance to sell the drug earlier? This is not rocket science this is common sense. |
|
|
|
Post by patten1962 on Feb 3, 2016 20:33:25 GMT -5
I was told by Sanofi rep they are in until July. But who knows if he is right? I was pleased with the call. Question is, people that are long, Are they looking at the call objectively? Based on your recent posts - I would say that you are the one that is not looking at this objectively, or at least not aware of enough of the company history to be wholly objective. You do realize that at the current burn rate they will be out of money in July? Getting them the rights back at the point does them no good, and if they can't sign another partner until they get the rights back then that basically spells BK unless Mann steps in again and drops a huge loan. U make a great point. Just wondering how much matt can tell us? |
|
|
|
Post by greg on Feb 3, 2016 20:42:04 GMT -5
I listened to the call then read comments on both this board and the other one. So far saw a lot a negative points on both boards from calling Pffefer and the management team morons..the other board, to how GS is planning a downgrade, (I don't understand why a company so great and powerful like GS would waste time downgrading a stock under a dollar?...a bit of sarcasm here) I did not see anyone address the fact that MNKD can do little until April, when full control of AFREZZA is returned by Sanofi. I personally liked the fact that Matt addressed the individual investor questions/comments before he took questions from the rocket scientists at GS, Piper, and whoever the other guy was. I'm willing to wait, give them a chance to put their plan in action and then evaluate. I've been negative on the company myself in the past but Hakan is gone as will be the elephant in the room Sanofi in April. Maybe Matt and team have learned the Jacques Clouseau lesson in partners...trust everyone but trust no one. I did the reverse. I read most of the comments first and then listened to the call. Not surprisingly, given the large short interest and the many folks that do their bidding, my feelings after the reading was the polar opposite of my feelings after the listening. Like you, I am willing to wait, believing there's far more upside potential than downside risk. And like many others, I look forward to the day that the clowns at GS and on these pages get their due; I can't imagine olsen feels too good about doing his shameless and obvious crap on a penny stock. |
|
|
|
Post by obamayoumama on Feb 3, 2016 20:43:29 GMT -5
That's a fair assessment. If people read the January PR that announced the termination, they'll read that transfer can take place April 5 if Sanofi's reason is that Afrezza is not commercially feasible. But you'll notice in the PR that Sanofi may choose an alternate 6-month notice for any reason, which would put the termination date on July 4. One of the questions I had asked to be addressed was if Sanofi has communicated the official termination date to MannKind. I'll need to read the transcript to determine if Matt stated that the termination date "could be" April 5 or "will be". I read it that way from day one but half the members here labeled it as FUD One of the moderators or board owners even corrected me that MNKD had the rights now. Why would SNY give it back early? They dug the knife in our back with their statement that Afrezza has no shot at gaining any traction and now they are going to turn it over early? If SNY truly feels threatened by MNKD then why would they give them a chance to sell the drug earlier? This is not rocket science this is common sense. I would be surprised if SNY didn't want to pay MNKD a parting gift and forgive the debt for an agreement by MNKd not to sue them |
|
|
|
Post by mnholdem on Feb 3, 2016 22:11:52 GMT -5
Perhaps we should look at this another way. The point of these transitions following a termination of agreement is to protect the distributor's reputation and to protect the patient. Is it also possible that Sanofi may be more cooperative than many of us expect?
Can Sanofi really afford to project the image of being a lousy choice for global pharmaceutical partnership with all the other drug development companies out there?
It's a possibility that Sanofi wants this parting to be amicable, although I would be stunned if, as part of the transition, Sanofi agreed to lower prices immediately. If they wanted to hurt MannKind, then Sanofi was stupid to go ahead and publicly state that Afrezza is not commercially viable in the U.S. because by saying that they paint themselves into a corner. If Sanofi-Aventis really had wanted to hurt MannKind to try to stop Afrezza, they would have claimed the "for any reason" clause and then terminated with a 6-month notice to force MannKind to burn through another three months cash. Now that they've "gone public" that they haven't been able sell Afrezza in spite of their "best efforts", they'll have to speed up the transition under the 90-day notice provision. I don't see much material that needs to be transferred. After all, they didn't do that much!
My point is simply that Sanofi may not want to project a "bad partner" image and so may want this transfer to go nicely... and fast. Concern for their own reputation is also why a think that a cash or debt settlement may be possible. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Feb 3, 2016 22:16:09 GMT -5
That's a fair assessment. If people read the January PR that announced the termination, they'll read that transfer can take place April 5 if Sanofi's reason is that Afrezza is not commercially feasible. But you'll notice in the PR that Sanofi may choose an alternate 6-month notice for any reason, which would put the termination date on July 4. One of the questions I had asked to be addressed was if Sanofi has communicated the official termination date to MannKind. I'll need to read the transcript to determine if Matt stated that the termination date "could be" April 5 or "will be". I was told by Sanofi rep they are in until July. But who knows if he is right? I was pleased with the call. Question is, people that are long, Are they looking at the call objectively? Docfrezza posted this also why people seem to ignore these things are beyond me |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Feb 3, 2016 22:17:46 GMT -5
I read it that way from day one but half the members here labeled it as FUD One of the moderators or board owners even corrected me that MNKD had the rights now. Why would SNY give it back early? They dug the knife in our back with their statement that Afrezza has no shot at gaining any traction and now they are going to turn it over early? If SNY truly feels threatened by MNKD then why would they give them a chance to sell the drug earlier? This is not rocket science this is common sense. I would be surprised if SNY didn't want to pay MNKD a parting gift and forgive the debt for an agreement by MNKd not to sue them I was prett happy when Matt mentioned this at JPM conf but was a little upset it was not touched upon again today. The fact that him seemed short about SNY makes me wonder if this is coming to terms. However it would be a fucking life line of life lines! |
|
